EUCTR2020-004270-22-ITActive, not recruitingPhase 1
PHASE II STUDY OF TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) GIVEN IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE (VP-16) AS CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH HIGH-RISK ACUTE LYMPHOCYTIC OR MYELOGENOUS LEUKEMIA - TMLI
IRCCS-A.O.U. SAN MARTINO-IST0 sites34 target enrollmentStarted: August 17, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 34
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Age =18 to =60 years
- •Karnofsky performance status must be =70%
- •Patients with acute lymphocytic leukemia or acute myelogenous leukemia who are not in first remission or second remission, i.e. after failing induction therapy, or in relapse, or beyond second remission.
- •All candidates for this study must have an HLA (A,B,C,DR) identical sibling who is willing to donate bone marrow or primed blood stem cells, a 10/10 allele matched unrelated donor.
- •Patients must undergo cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm, and an ejection fraction of =50% established by MUGA or echocardiogram.
- •Patients must have a serum creatinine of less than or equal to 1.3 mg/dL or creatinine clearance > 80ml/min.
- •Patients must have bilirubin of less than or equal to 1.5mg/dL and should also have an SGOT and SGPT less than 5 times the upper limit of normal
- •Pulmonary function tests including DLCO will be performed. FEV1and DLCO should be greater than 50% of predicted normal value.
- •The time from the end last induction or re-induction attempt should be greater than or equal to 14 days.
- •All patients must have a psychosocial evaluation prior to transplant as per COH SOP
- •All subjects must have the ability to understand and the willingness to sign a written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Patients who have received a prior autologous or allogeneic transplant are excluded
- •Uncontrolled inter-current illness including, but not limited to ongoing or active or poorly controlled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, poorly controlled pulmonary disease or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant and lactating women are excluded from this study.
- •Patients who do not agree to practice effective forms of contraception.
- •Patients who received radiation therapy that would exclude them from the use of total body irradiation are ineligible and individual patients who have received prior radiation must be presented to the study PI for eligibility determination.
- •Patients with active 2nd malignancies other than AML, ALL or MDS.
- •Any psychiatric, social or compliance issues that, in the treating physician opinion, will interfere with completion of the transplant treatment and follow up.
Investigators
Similar Trials
Recruiting
Phase 2
IMRT-TMLI PIImalignant hematological diseasesJPRN-jRCT1032230247Murofushi Keiko28
Completed
Not Applicable
Phase I trial of Total Marrow and Lymphoid Irradiation Transplantation ConditioningHematologic malignancyJPRN-UMIN000037581Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital9
Active, not recruiting
Phase 2
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute LeukemiaAcute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeMyelodysplastic SyndromeAcute Lymphoblastic LeukemiaNCT04262843City of Hope Medical Center33
Active, not recruiting
Phase 2
Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic SyndromesMyelodysplastic SyndromesAcute Myeloid LeukemiaNCT03121014University of Illinois at Chicago38
Recruiting
Phase 2
Evaluation of Lymphatic flow using indocyanine green fluorescence imagingColorectal adenocarcinomaJPRN-jRCTs061210023Kondo Akihiro100